Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 282838
Licensor Patents mean
US patent 6,585,995 Methods and compositions for treating platelet-related disorders
US Patent Application 20130022671
Essential thrombocythemia (ET) is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow.
Cardiovascular Field means the direct prevention, treatment, diagnosis of myocardial infarction, strokes and peripheral arterial disease in humans or other animals. For sake of clarity the Cardiovascular Field will not include the prevention, treatment or diagnosis of conditions that may ultimately lead to a decrease in the risk of thrombotic events, such as Myeloproliferative Disorders and other hematological indications.
IPSCIO Record ID: 204382
The Licensor is a biotechnology company, developing and commercializing drugs and devices for the control of hyperplasia associated with vascular procedures and control of cardiovascular risk factors.
IPSCIO Record ID: 4475
The license cites the following as relevant US patent 6,585,995 B1; US Patent Application 20130022671; Issued UK Patent GB 2462022B; Issued UK Patent GB 2460915B; PCT/US2009/003632 (Publication No. WO 2010/005480)
US patent 6,585,995 B1
US Patent Application 20130022671
Issued UK Patent GB 2462022B
Issued UK Patent GB 2460915B
PCT/US2009/003632 (Publication No. WO 2010/005480) and related regional and national applications
Myeloproliferative disorders is the name for a group of conditions that cause blood cells, platelets, white blood cells, and red blood cells, to grow abnormally in the bone marrow.
IPSCIO Record ID: 203285
Licensor grants a non-transferable, non-exclusive license, with the right to sublicense, under the Licensor Other Patent Rights solely to the extent reasonably necessary to make, use (including in activities directed at the research and Development of Licensed Compounds), have made, sell, offer to sell, export and import and otherwise exploit or Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.
6,670,386 – Bicyclic modulators of androgen receptor function
The licensed compounds and patents relate to controlling various diseases and cancers.
IPSCIO Record ID: 269086
The Licensor is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Adult chronic immune thrombocytopenic purpura (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes (the cells that produce platelets in the bone marrow), causing a decrease in platelet production. This results in a low blood platelet count (thrombocytopenia) that may produce bruising or excessive bleeding.